DFTX Definium Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$45.08

Period return

+28.11 (+165.65%)

Volume

1.5M

2026-07-21O $42.5 H $45.17 L $41.57 C $45.08MA5 $44.39MA20 $44.52MA60 $30.16MA120 $24.47

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — Point72 Asset Management, L.P.
신규 편입 · 포트폴리오 비중 0.01%
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.02%
2026. 05. 09.LowBUY2 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 04. 22.LowBUY3 months ago
Leerink Partners: Outperform
US analyst rating / recommendation change.
2026. 04. 17.MediumBUY3 months ago
Stifel: Buy
US analyst rating / recommendation change.
2026. 04. 17.LowBUY3 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 04. 10.MediumBUY3 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 03. 02.LowBUY5 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 02. 24.MediumBUY5 months ago
Wolfe Research: Outperform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $39.47 · 15 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

Sector: Healthcare
Industry: Biotechnology
HQ: New York, NY, United States
Fiscal year end: —
Employees: 105
IPO date: —

View details →

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	1,201,610	$22.71M	0.02%	—	New position
2	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	175,490	$3.32M	0.01%	—	New position

Definium Therapeutics, Inc.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 09.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 04. 22.	Leerink Partners	—	Maintain	Outperform → Outperform	—	Leerink Partners: Outperform
2026. 04. 17.	Stifel	—	Initiate coverage	— → Buy	—	Stifel: Buy
2026. 04. 17.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy
2026. 04. 10.	Piper Sandler	—	Initiate coverage	— → Overweight	—	Piper Sandler: Overweight
2026. 03. 02.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy